Latest Breaking News On - Kevino hayer - Page 1 : comparemela.com

Synnovation Therapeutics Announces First Patient Dosed in Phase I Trial with SNV1521, a PARP1 Selective Inhibitor for the Treatment of Solid Tumors

WILMINGTON, Del., March 11, 2024 Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, today announced that the first patient has been dosed in a Phase I trial evaluating SNV1521 in patients with solid tumors. SNV1521 is a potentially best-in-class, potent, highly selective and CNS penetrant PARP1 inhibitor.

United statesTimothy yapKevin ohayerHead of clinical development at synnovationUniversity of texas md anderson cancer centerSynnovation therapeuticsInvestigational cancer therapeuticsCancer centerKevino hayerSenior vice presidentClinical development

Incyte vets, with phase 1 within reach, raise $102M for new biotech to create better PARP, PI3K drugs

Incyte vets, with phase 1 within reach, raise $102M for new biotech to create better PARP, PI3K drugs
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Phillip liuWenqing yaoLiangxing wuKevin ohayerMerck kgaMerck kgaaMerck coJiangsu hengrui pharmaceuticalsNerviano medical sciencesSynnovation therapeuticsJiangsu hengruiKevino hayer